Relationship between serum osteocalcin/undercarboxylated osteocalcin and type 2 diabetes: A systematic review/meta-analysis study protocol by Liu, Yihui et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
3-12-2019 
Relationship between serum osteocalcin/undercarboxylated 
osteocalcin and type 2 diabetes: A systematic review/meta-
analysis study protocol 
Yihui Liu 
Xiaoying Liu 
Joshua R. Lewis 
Edith Cowan University, joshua.lewis@ecu.edu.au 
Kaye Brock 
Tara C. Brennan-Speranza 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Liu, Y., Liu, X., Lewis, J. R., Brock, K., Brennan-Speranza, T. C., & Teixeira-Pinto, A. (2019). Relationship 
between serum osteocalcin/undercarboxylated osteocalcin and type 2 diabetes: A systematic review/
meta-analysis study protocol. DOI: https://doi.org/10.1136/bmjopen-2018-023918 
10.1136/bmjopen-2018-023918 
Liu, Y., Liu, X., Lewis, J. R., Brock, K., Brennan-Speranza, T. C., & Teixeira-Pinto, A. (2019). Relationship between 
serum osteocalcin/undercarboxylated osteocalcin and type 2 diabetes: A systematic review/meta-analysis study 
protocol. BMJ Open, 9(3), Article e023918. Available here 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/6366 
Authors 
Yihui Liu, Xiaoying Liu, Joshua R. Lewis, Kaye Brock, Tara C. Brennan-Speranza, and Armando Teixeira-
Pinto 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/6366 
1Liu Y, et al. BMJ Open 2019;9:e023918. doi:10.1136/bmjopen-2018-023918
Open access 
Relationship between serum osteocalcin/
undercarboxylated osteocalcin and type 2 
diabetes: a systematic review/meta-
analysis study protocol
Yihui Liu,1,2 Xiaoying Liu,2 Joshua R Lewis,1,3 Kaye Brock,4 
Tara C Brennan-Speranza,4 Armando Teixeira-Pinto1,2
To cite: Liu Y, Liu X, R 
Lewis J, et al.  Relationship 
between serum osteocalcin/
undercarboxylated osteocalcin 
and type 2 diabetes: a 
systematic review/meta-analysis 
study protocol. BMJ Open 
2019;9:e023918. doi:10.1136/
bmjopen-2018-023918
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
023918).
Received 7 June 2018
Revised 19 January 2019
Accepted 28 January 2019
1Centre for Kidney Research, 
Children's Hospital, Westmead, 
New South Wales, Australia
2School Public Health, Faculty of 
Medicine and Health, University 
of Sydney, Camperdown, New 
South Wales, Australia
3School of Medicine, Faculty 
of Medicine and Health, The 
University of Western Australia, 
Perth, Western Australia, 
Australia
4School of Medical Sciences, 
University of Sydney, 
Camperdown, New South Wales, 
Australia
Correspondence to
Dr Armando Teixeira-Pinto;  
 armando. teixeira- pinto@ sydney. 
edu. au
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction The global burden of type 2 diabetes 
(T2DM) is steadily increasing. Experimental studies 
have demonstrated that a novel hormone secreted by 
bone cells, osteocalcin (OC), can stimulate beta-cell 
proliferation and improve insulin sensitivity in mice. 
Observational studies in humans have investigated the 
relationship between OC and metabolic parameters, and 
T2DM. Importantly, few studies have reported on the 
undercarboxylated form of OC (ucOC), which is the putative 
active form of OC suggested to affect glucose metabolism.
Objectives We will conduct a systematic review and 
meta-analysis to: (1) compare the levels of serum OC and 
ucOC between T2DM and normal glucose-tolerant controls 
(NGC); (2) investigate the risk ratios between serum 
OC and ucOC, and T2DM; (3) determine the correlation 
coefficient between OC and ucOC and fasting insulin 
levels, homeostatic model assessment-insulin resistance, 
haemoglobin A1c and fasting glucose levels and (4) 
explore potential sources of between-study heterogeneity. 
The secondary objective is to compare the serum OC and 
ucOC between pre-diabetes (PD) and NGC and between 
T2DM and PD.
hods and analysis This study will report items in 
line with the guidelines outlined in preferred reporting 
items for systematic reviews and meta-analysis of 
observational studies in epidemiology. We will include 
observational studies (cohort, case-control and cross-
sectional studies) and intervention studies with baseline 
data. Three databases (MEDLINE, EMBASE and SCOPUS) 
will be searched from inception until July 2018 without 
language restrictions. Two reviewers will independently 
screen the titles and abstracts and conduct a full-text 
assessment to identify eligible studies. Discrepancies will 
be resolved by consensus with a third reviewer. The risk 
of bias assessment will be conducted by two reviewers 
independently based on the Newcastle-Ottawa Scale. 
Potential sources of between-study heterogeneity will be 
tested using meta-regression/subgroup analyses. Contour-
enhanced funnel plots and Egger’s test will be used to 
identify potential publication bias.
Ethics and dissemination Formal ethical approval is 
not required. We will disseminate the results to a peer-
reviewed publication and conference presentation.
PrOsPErO registration number CRD42017073127.
IntrOduCtIOn 
The disease burden attributed to diabetes is 
high. Currently, around 425 million people 
have diabetes, with 90% of these having 
type 2 diabetes (T2DM).1 It is estimated 
that by 2045, this figure will have increased 
to 629 million people.1 Patients with T2DM 
present increased levels of glucose than 
people with normal glycaemic metabolism. 
Also, those patients have increased risks of 
other complications, such as heart attacks, 
strokes, diabetic retinopathy and renal 
disease.2 
Correspondingly, several organs become 
the targets to treat, prevent or predict 
diabetes, such as pancreatic beta cells, muscle, 
liver, adipose tissue, kidney, the gastrointes-
tinal tract or the brain.3 Interestingly, a recent 
study has identified a new potential tissue 
to treat diabetes: the skeleton and bone. 
Increasing numbers of osteokines secreted by 
strengths and limitations of this study
 ► This review will propose a sensitive search strategy 
to include more eligible observational studies (co-
hort, case-control and cross-sectional studies) than 
previous meta-analyses.
 ► The review will assess and synthesise data on both 
forms of osteocalcin (OC; total OC and undercarbox-
ylated OC [ucOC]), potentially being more relevant to 
the endocrine function in humans.
 ► The design of the review considers the early to late 
stages of diabetes, which will indicate whether the 
relationship between OC and impaired glucose me-
tabolism is altered during progressively poorer glu-
cose control.
 ► Sources of heterogeneity will be explored using me-
ta-regression/subgroup analyses.
 ► The main limitation of the current study is only in-
cluding observational studies (cohort, case-control 
and cross-sectional studies).
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skeleton and bone exhibit regulatory function in glucose 
metabolism.3
Osteocalcin (OC) is an osteoblast-secreted protein that 
plays a role in the communication between the skeleton 
and glucose homeostasis. There are two forms of OC: 
undercarboxylated osteocalcin (ucOC) and carboxylated 
osteocalcin (cOC).4 cOC contributes to the extracellular 
bone matrix, while ucOC is likely the active form of OC in 
the circulation.5 Both cOC and ucOC are present in the 
circulation, and their combined amount is referred to as 
total osteocalcin (TOC).5 TOC is considered a marker of 
bone turnover.6
A potential endocrine function of OC was first suggested 
in 2007. Lee et al and Ferron et al reported OC-mediated 
glucose homeostasis via stimulating beta-cell prolifera-
tion and adiponectin secretion in mice.7 8 The endocrine 
actions of OC involve increasing insulin synthesis and 
secretion by beta-cells and improved insulin sensitivity 
by promoting adiponectin secretion in adipocytes.7 8 The 
high-fat diet experimental study revealed that bone could 
become insulin resistant by inhibiting the activation of 
OC.9 However, reported associations between OC and 
T2DM in humans have yielded conflicting results.10–13 
Lerchbaum et al reported that high OC level was associ-
ated with reduced risk of developing T2DM in a popu-
lation-based study (OR, 0.57; 95% CI: 0.46 to 0.70).14 In 
a cross-sectional study of patients with poorly controlled 
T2DM, Achemlal et al reported that serum levels of OC were 
significantly lower in T2DM compared with age-matched 
controls,15 while Bao et al observed that increased serum 
levels of OC were associated with improved glucose 
control.16 Yeap et al found that both TOC and ucOC were 
associated with reduced risk of diabetes in a cohort of 
community-dwelling elderly men (OR, 0.60; 95% CI: 0.50 
to 0.72 for TOC, and OR, 0.55; 95% CI: 0.47 to 0.64 for 
ucOC).17 In contrast, a case-control study conducted by 
Zwakenberg et al with 1635 participants indicated a lack 
of association between TOC/ucOC and the risk of T2DM 
(OR, 0.97; 95% CI: 0.69 to 1.36 for TOC, and OR, 0.88; 
95% CI: 0.61 to 1.27 for ucOC).18
Two previously published systematic reviews/meta-anal-
yses reported decreased serum levels of TOC in people 
with T2DM compared with controls in 2015. However, 
these reviews only found a small number of published 
studies and did not investigate ucOC.19–21 The mean 
differences in T2DM compared with normal glucose 
tolerance controls from the three reviews showed similar 
results (−3.31 ng/mL (−4.04, –2.57) from Kunutsor et al; 
−2.87 ng/mL (−3.76,–1.98) from Liu C et al and −2.51 ng/
mL (−3.01,–2.01) from Hygum et al).19–21 Both of the 
reviews by Kunutsor et al and Liu C et al only found a 
small number (n=4) of cohort studies.19 20 In addition, 
studies reporting the associations between ucOC and 
glucose homeostasis in T2DM have not been adequately 
meta-analysed.20
An increasing number of epidemiological studies have 
been continuously published in the recent 3 years following 
two systematic reviews/meta-analyses in 2015, signalling 
a need for up-to-date systematic review/meta-analysis. In 
2017, Takashi et al showed that ucOC could predict insulin 
secretion in patients with T2DM.22 They conducted the 
study in 41 Japanese patients with T2DM with a mean 
age of about 59 years22 The result showed a correlation 
between ucOC and homeostatic model assessment of 
beta-cell function (r=0.36, P=0.011).22 In a cross-sectional 
study of 69 volunteers, OC was found to be suppressed 
with insulin resistance, regardless of obesity or fat mass 
at significantly lower levels shown in controls compared 
with T2DM or insulin resistant obesity.23 However, only 
a few interventional studies/clinical trials were found 
in our scope search in MEDLINE (online appendix 1). 
Only three clinical studies were conducted after 2015 and 
might be eligible for inclusion in the present review.24–26 
Ghiraldini et al designed a clinical trial in 32 T2DM 
patients and 19 patients without diabetes. Baseline data 
indicated that OC levels were higher in systematically 
healthy patients than those with better-controlled T2DM 
while poorly controlled T2DM patients had the highest 
OC levels.26
Some observational studies have reported decreased 
OC concentrations in pre-diabetics (PD) compared 
with normal glucose tolerance controls, while Aoki 
et al indicated an increase in OC concentration during 
the early stage of diabetes.27–29 Therefore, conducting 
meta-analyses comparing the OC levels between PD 
and normal glucose controls and comparing OC levels 
between T2DM and PD may contribute to the investi-
gation between OC and glucose homeostasis in patients 
with diabetes.
Another unsolved issue in the previously published 
meta-analyses is the high between-study heterogeneity. 
Previous reviews explored different sources of hetero-
geneity with modest success.19 20 Starup-Linde et al 
conducted subgroup analysis according to sex, age and 
menopausal status in women.30 Liu C et al attempted to 
explain the heterogeneity by sex and OC assay methods.20 
Kunutsor et al conducted subgroup analyses according 
to study design and degree of confounders of risk esti-
mates.19 Hygum et al performed a meta-regression anal-
ysis to investigate the extent to which heterogeneity was 
explained by haemoglobin A1c (HbA1c) levels.21
Therefore, the present systematic review/meta-anal-
ysis will use a more comprehensive search strategy to 
identify more prospective studies, thereby increasing 
the statistical power. Second, we will search for studies 
reporting the association between ucOC and glucose 
metabolism. Third, we will identify studies comparing 
the OC concentrations between PD and normal glucose 
controls, and between T2DM and PD. Lastly, by systemati-
cally exploring potential sources of heterogeneity we may 
explain previous conflicting findings.
ObjECtIvEs
The present systematic review and meta-analysis aims to: 
(1) compare the levels of serum OC and ucOC between 
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T2DM and normal glucose-tolerant controls (NGC); (2) 
investigate the risk ratios between serum OC and ucOC, 
and T2DM; (3) determine the correlation coefficient 
between OC and ucOC, and fasting insulin levels, homeo-
static model assessment-insulin resistance (HOMA-IR), 
HbA1c and fasting glucose levels (FPG) and (4) explore 
potential sources of between-study heterogeneity. The 
secondary objective is to compare the serum OC and 
ucOC between PD and NGC, and between T2DM and PD.
MEthOds And AnAlysIs
We designed this systematic review and meta-analysis in 
adherence to the guidelines of preferred reporting items 
for systematic reviews and meta-analysis (PRISMA) and 
meta-analysis of Observational Studies in Epidemiology 
(MOOSE).31 32 The process of the proposed protocol is 
shown in figure 1, and the PRISMA checklist shown in 
online appendix 2.
Patients and public involvement statement
There is no patient or public involved in this systematic 
review/meta-analysis.
Eligibility criteria for studies included in the review
Inclusion and exclusion criteria
Participants
Participants should be adult humans (older than 18 years 
old), with T2DM at the baseline or developed T2DM 
afterwards; not have any conditions that can affect bone 
metabolism or with medications that affect bone metabo-
lism; and could be on anti-diabetic treatment.
Exclude:
1. Children or adolescents (younger than 18 years), and 
pregnant or lactating women due to altered bone 
turnover marker levels.
2. Patients with a disease that either affects bone metab-
olism or glucose metabolism.
3. Patients with type 1 diabetes and/or gestational dia-
betes as they are pathophysiologically different from 
patients with type 2 diabetes (T2DM).
4. Patients with Cushing's disease or Cushing's syn-
drome as they have disordered metabolism.
5. Patients with hormonal disorders. For instance, 
growth-hormone deficiency or excess.
6. Patients with hyperparathyroidism or hypoparathy-
roidism or other diseases that affect thyroid function 
Figure 1 The process of the proposed protocol.
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due to increased osteocalcin (OC) levels and changes 
in metabolism.
7. Patients with liver dysfunction (alanine transaminase 
level >3 times upper limit of normal).
8. Patients with impaired kidney function as described 
below:
 – Chronic renal disease patients with glomerular 
filtration rate below 30 mL/min·1.73 m2 at stage 
four or five, or
 – Chronic renal disease patients with serum cre-
atinine level over 2.07 mg/dL, or renal osteo-
dystrophy, or kidney transplant as 21%–50% 
of kidney transplant recipients may develop 
secondary hyperparathyroidism after kidney 
transplantation or when treated with dialysis or 
hemodialysis.
9. Patients with Paget’s disease as they have disordered 
bone metabolism.
10. Patients with osteomalacia as it is a severe bone dis-
ease and affects bone metabolism.
11. Patients with cancer or tumours. For example, bone 
cancer metastases could affect bone turnover marker 
levels.
12. Patients with HIV infection.
13. Patients with sepsis as they have disordered immune 
response caused by infections.
14. Patients on medications that affect bone metabolism:
 – Antiresorptive or anabolic therapy for osteoporo-
sis and selective oestrogen receptor modulators 
(such as bisphosphonates, alendronate, etidro-
nate, raloxifene, denosumab and teriparatide).
 – Oestrogen replacement therapy.
 – Glucocorticoids and thiazide diuretics.
15. Patients treated with surgery that directly affects hor-
mone or thyroid function (ie, thyroidectomy, oopho-
rectomy and hysterectomy).
Note:
1. We include intervention studies that reported baseline 
data of OC and T2DM. Accordingly, we will eliminate 
observational studies with more than 20% of the co-
hort taking above non-eligible therapy.
2. We included T2DM with diabetic medications, but 
they will be assessed using subgroup analysis by 
medication status. Anti-diabetic medications that 
affect OC/ucOC levels include insulin therapy, glu-
cagon-like peptide-1 (GLP-1) receptor agonists, and 
thiazolidinediones.
Study types
Observational studies are eligible for inclusion: cohort 
studies (both prospective and retrospective cohort 
studies), case-control studies and cross-sectional studies, 
reporting eligible exposure(s) and outcome(s).
We will exclude reviews, commentaries, short surveys, 
case reports, and letters.
Interventional studies (including randomised 
controlled trials) will be used if they provide eligible 
cross-sectional data at the baseline before intervention.
Exposure(s)
OC levels are identified from ELISA, electrochemilumi-
nescence immunoassay, immunoradiometric assay, radio-
immunoassay and hydroxylapatite binding assay. The 
standard unit for OC is ng/mL; thus, other presented 
groups for OC (eg, nmol/L) will be converted to ng/mL.
Measures of OC
 ► Total serum OC levels (ng/mL).
 ► ucOC levels (ng/mL).
 ► OC categorised as low (reference) and high groups. 
Tertile, quartile or quantile are the common cate-
gories used for classifying different levels of TOC or 
ucOC.
Outcome(s)
Measures of T2DM
 ► Diabetes status categorised as T2DM disease or normal 
controls (reference).
 ► As some studies may categorise diabetes states as 
insulin-dependent diabetes mellitus and non-insulin 
dependent diabetes mellitus (NIDDM), NIDDM will 
be used and presented as T2DM.
Exclude type 1 diabetes and gestational diabetes as they 
are pathophysiologically different compared with T2DM.
secondary outcome(s)
 ► Impaired glucose tolerance/impaired fasting glucose: 
that is the pre-diabetic state with a higher risk of devel-
oping T2DM.
 ► HbA1c levels categorised as T2DM, PD and healthy 
controls (reference) by HbA1c rates over 6.5%, 
between 5.7% and 6.5%, and below 5.7%, respectively.
 ► Fasting plasma glucose levels categorised as diabetes, 
PD and healthy controls (reference) by FPG levels 
over 126 mg/dL, between 100 and 126 mg/dL, and 
below 100 mg/dL, respectively.
study design
Search strategies
A comprehensive literature search within MEDLINE, 
EMBASE and SCOPUS databases will be conducted to 
source all possible relevant studies for the present review. 
There is no language restriction, and non-English arti-
cles will be translated when possible and evaluated for 
eligibility. There is no time restriction. We may include 
conference proceedings and abstracts if necessary. We 
will further conduct reference list searches of each avail-
able paper. If duplicate publications of the same study are 
retrieved, the most relevant and up to date paper with 
more complete data will be included. The detailed search 
strategy is shown in table 1.
Process for selecting studies
One author will set-up the search strategy and store the 
search results in Endnote X7. The search strategy and 
recorded search results will then be checked by another 
investigator. Two or more independent investigators will 
perform the abstract screening (to remove duplicate 
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records of the same report and to include eligible arti-
cles), and full-text assessment (to acquire full-texts of 
available studies and to construct citation lists of eligible 
items). If a discrepancy arises, the disagreement will be 
discussed with investigators by email or face-to-face meet-
ings before reaching a final decision.
data extraction
Two authors will independently extract data from studies 
that are eligible for full-text assessment. If any discrep-
ancy arises, a third reviewer will examine the data. All 
extracted data will be saved in an Excel spreadsheet.
Eligible extracted items: author and publication year, study 
design, study base, sample size, sex and postmenopausal 
status in females, age, ethnicity, country, OC assay methods, 
obesity measurements (body mass index or waist circumfer-
ence), duration of diabetes, anti-diabetic medications status, 
vitamin K supplementation/anti-vitamin K drugs, vitamin 
D supplementation, TOC/ucOC levels in groups, any risk 
estimate between TOC/ucOC and T2DM, any association 
between TOC/ucOC and HbA1c and/or FPG in T2DM, any 
association between TOC/ucOC and PD and/or impaired 
glucose tolerance/impaired fasting glucose, any associa-
tion between TOC/ucOC and standard glucose controls, 
and any association between TOC/ucOC and HOMA-IR or 
HOMA-beta in T2DM.
risk of bias assessment
The methodological quality will be assessed using the Newcas-
tle-Ottawa Scale (NOS). Cohort and case-control studies can 
be assessed by three main parts in the NOS: selection, compa-
rability and outcome/exposure.33 The maximum score is 
nine points.33 A higher score indicates better methodolog-
ical quality of the individual study.33 Cross-sectional studies 
can be assessed using the modified NOS.34 The maximum 
score is 10 points for the modified NOS, representing the 
highest quality.34 The quality assessment template can be 
found in the supplementary materials (online appendix 3).
statistical analysis and data synthesis
Mean differences with 95% CI will be calculated between 
T2DM and NGC, between PD and NGT, and between T2DM 
and PD. Estimates of effect size will be expressed as relative 
risk with 95% CI for cohort studies and OR with 95% CI for 
case-control and cross-sectional studies. OR is expressed as 
one increased SD of OC to the risk of developing T2DM. 
Papers reporting other forms of OR will be translated to per 
increased SD of OC if a logistic regression model is used. 
Pearson’s correlation coefficient will be analysed by investi-
gating the relationships between TOC or ucOC and fasting 
insulin levels. Studies that only have medians and ranges 
or IQRs will be transformed to means and SD.35 36 Further-
more, log-transformed data will be converted to raw statistics 
before subjecting to analyses.37 We will assess publication bias 
of mean differences and risk estimates by visual inspection 
of the funnel plots38 39 Egger’s test will be used to assess the 
publication bias when there is a large number of studies.38 We 
will evaluate heterogeneity employing the I2 statistic by study 
ID which quantifies inconsistency across studies to assess the 
impact of heterogeneity on the meta-analysis.40 I2 represents 
the degree of heterogeneity. I2 thresholds of 0%–40%, 
30%–60%, 50%–90% and 75%–100% indicate possibilities 
of low, moderate, substantial and considerable heterogeneity, 
Table 1 Detailed search strategy in databases: MEDLINE, EMBASE and SCOPUS
MEDLINE (Ovid SP) EMBASE (Ovid SP) SCOPUS
1. exp osteocalcin
2. osteocalcin.mp
3. bone gla protein.mp
4. vitamin k?dependent bone protein*.mp
5. 1 or 2 or 3 or 4
6. exp diabetes mellitus, Type 2/II
7. diabetes mellitus type 2/II.mp
8. (T2D* or NIDDM or ‘type 2’ or ‘type II’).tw
9. (non insulin$ depend$ or nonsinulin$depend$ 
or non insulin?depend$ or 
noninsulin?depend$).tw
10. exp Hyperglycemia
11. hyperglycemia.mp
12. hypergly?emi*.tw
13. exp Hemoglobin A/or exp Hemoglobin A, 
Glycosylated
14. HbA1c.mp
15. (‘HbA(1 c)’ or HbA1c or ‘HbA 1 c’ or 
(glycosylated or glycated) adj h?emoglobin)).
tw
16. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
or 15
17.  5 and 16
18. limit 17 to humans
1. exp osteocalcin
2. osteocalcin.mp
3. bone gla protein.mp
4. vitamin k?dependent bone 
protein*.mp
5. 1 and 2 and 3 and 4
6. exp non insulin dependent 
diabetes mellitus
7. exp diabetes mellitus 2/II
8. (T2D* or NIDDM or ‘type 2’ or 
‘type II’).tw
9. (prediabet* or pre diabet*).tw
10. hyperglyc?emi*.tw
11. 6 or 7 or 8 or 9 or 10
12. 5 and 11
13. limit 13 to (human and exclude 
medline journals)
(KEY ('osteocalcin')
OR KEY ('bone AND gla AND 
protein')
OR KEY ('bone AND turnover AND 
markers'))
AND (KEY ('diabetes AND mellitus')
OR KEY ('hemoglobin AND a1c')
OR KEY ('fasting AND plasma AND 
glucose'))
AND KEY ('human') AND (LIMIT-TO 
(DOCTYPE, ‘ar’))
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respectively.40 It is suggested to use Rstudio for conducting 
meta-analyses (V.1.1.419-2009-2019; RStudio). The ‘metafor’ 
package will be used to perform meta-regression analyses, 
meta-bias analyses and for assessing heterogeneities.41 Each 
p value of <0.05 indicates statistical significance.
Meta-regression/subgroup analysis
Meta-regression analysis and subgroup analysis will be 
applied to assess the sources of heterogeneity. Meta-regres-
sion will be used for continuous factors such as age, sample 
size and proportion of postmenopausal women. We will 
use subgroup analyses to identify potential sources of clin-
ical, methodological or statistical heterogeneity for cate-
gorical variables. We will also generate mix-effect models 
to evaluate the influence of multiple factors on the effect 
size. Random-effects models will be used, and p values of 
<0.01 will be considered statistically significant for subgroup 
analyses. Pre-planned subgroup analyses to explore statistical 
heterogeneity will include stratification by:
 ► Subgroups based on study design.
 ► Subgroups based on age.
 ► Subgroups based on sex. In addition, a subset based 
on menopausal status will be assessed among females.
 ► Subgroups based on ethnicity or race.
 ► Subgroups based on diabetic status (normal, PD, 
T2DM).
 ► Subgroups based on anti-diabetic medication status in 
T2DM.
 ► Subgroups based on obesity measurements (body 
mass index/waist circumference).
 ► Subgroups based on OC assay methods.
 ► Subgroups based on fasting measures and spot 
measures.
 ► Subgroups based on vitamin K supplementation/
anti-vitamin K drugs or vitamin D supplementation if 
data are available.
Publication bias and confidence in cumulative evidence
Publication bias assessment is based on graphical test 
(funnel plots) and Egger’s and Begg’s tests.38 39 The asym-
metry of the funnel plot suggests a higher risk of publica-
tion bias and vice versa.38 Statistically, Egger’s and Begg’s 
tests will be conducted using RStudio.
We will provide assurance of the quality of our results by 
applying the Grading of Recommendations Assessment 
Development and Evaluation (GRADE) tool. We will also 
present an evidence profile summary using GRADEpro 
software (http:// ims. cochrane. org/ gradepro). The 
quality checklist includes the following items: risk of bias 
assessment, consistency of results, directness of evidence 
and precision of the results.
dIsCussIOn
The current systematic review/meta-analysis constitutes 
an update and improvement to the current literature 
in several ways. First, we will provide more evidence 
compared with previous investigations in analysing the 
potential role/s OC plays in T2DM by increasing the 
number of eligible studies included in our up-to-date 
analysis. Second, we will investigate the sources of hetero-
geneity, explicitly by an increase in the number of factors 
such as age, sex, postmenopausal status in women, study 
design, ethnicity or regions, OC assays and medications 
on T2DM. This comprehensive analysis of heterogeneity 
may uncover the factor(s) responsible for the differences 
among already published studies. Third, we will produce 
a report not only on TOC levels, but also on ucOC levels. 
By including investigations on ucOC, we can determine 
the endocrine roles of both OC and ucOC in humans, 
if any. In addition, investigating the relationship in a 
subgroup of patients with PD will provide more details 
regarding the influence of OC (or ucOC) on glucose 
levels in a progressive T2DM status. The major limita-
tion of this review is that we will only be including obser-
vational studies as there is insufficient evidence from 
clinical trials, which will restrict study results in specific 
analyses. According to the search results for clinical 
studies, if there are any eligible interventional studies, we 
will include them but only use the baseline data in which 
case we will regard those studies as cross-sectional studies. 
Despite this disadvantage, there are still a large number 
of studies that could be used to pool a quantitative anal-
ysis and provide evidence according to concerns with 
heterogeneity. Our review will contribute to public health 
and clinical research for further investigations regarding 
the gap in the current literature.
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